ELB353
ELB353 is a phosphodiesterase 4 (PDE4) inhibitor, with therapeutic potential in chronic inflammatory disorders. The primary area of interest is chronic obstructive pulmonary disease (COPD), a disabilitating disorder with major unmet medical need.
Read more
VAP-1, a key inflammation receptor
Vascular Adhesion Protein-1 (VAP-1) is Biotie’s proprietary target and is protected by patents held by the company. VAP-1 has been shown to play a key role in mediating the inflammatory events associated with chronic diseases such as rheumatoid arthritis, psoriasis and diabetes.
Read more
VAP-1 Antibody
Biotie is developing a fully human monoclonal antibody which blocks VAP-1 function thereby allowing the inflammation to resolve.
Read more
Commercialization agreements
Seikagaku Corporation has signed a license agreement for the VAP-1 antibody rights covering Japan, Taiwan, Singapore, New Zealand, and Australia against up to USD 16.7 million in milestone payments plus royalties of sales in the territory. Biotie has already received USD 2.7 million from Seikagaku.
Biotie and Roche have signed an option agreement for Biotie’s fully human antibody program targeting VAP-1 in inflammatory diseases. Roche has paid Biotie EUR 5 million, which grants Roche an exclusive option right to an exclusive, worldwide license agreement for Biotie’s VAP-1 antibody, excluding Japan, Taiwan, Singapore, New Zealand and Australia. The initial option right will end upon completion of phase I.
Roche and Biotie are further collaborating in order to develop small molecule VAP-1 SSAO inhibitors to Roche specifications. Under the terms of the collaboration, both parties carry their own costs, but Biotie retains ownership of the developed compounds until Roche chooses to exercise its option for in-licensing. Under the terms of the collaboration and option agreement, Roche may pay Biotie up to 5 million euros to maintain its exclusive option for rest-of-world rights excluding Seikagaku’s territory (Japan, Taiwan, Singapore, New Zealand and Australia).
Biotie and Seikagaku have signed an option agreement for the VAP-1 enzyme inhibitor. The option is covering the same territory as Seikagaku’s license for the VAP-1 monoclonal antibody. If Seikagaku exercises its option, Biotie will receive up to USD 16.7 million in milestone payments plus royalties of sales in the territory based on the pre-negotiated licensing agreement. After the opt-in Seikagaku will be responsible for the clinical development of the product in its territory.
----
Updated April 2009